^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    FoundationOne® Liquid CDx

    Company:
    Roche
    Type:
    FDA Approved
    Related tests:
    1year
    Unique spectrum of BRAF alts in prostate cancer! 👉3% BRAF activated, mostly rearrangements and K601E. 👉Diverse BRAF fusions detected both in tissue DNA (F1CDx) and liquid ctDNA (F1LCDx). Love the teamwork here!🙌 @neerajaiims @montypal @EAntonarakis @HTukachinsky ()
    Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF fusion • BRAF K601E • BRAF K601
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx
    over2years
    Currently helping a patient w/advanced #GallbladderCancer. Their @FoundationOne Liquid CDx revealed a FGFR2 splice site 2038-78_*7del91; relevant to current discussion in this thread? (@GraceCordovano)
    Clinical
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FoundationOne® Liquid CDx
    over3years
    #FDA Approves FoundationOne Liquid CDx for Solid Tumors @US_FDA https://t.co/CepgPqdjpY (@OncLive)
    FDA event
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx
    4years
    "#Chugai Files for #FoundationOne #LiquidCDx Aiming to Provide #BloodBased Comprehensive Genomic Profiling for #SolidTumors https://t.co/TgWo90PNJi" (@1stOncology)
    FoundationOne® Liquid CDx